{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:35:25Z","timestamp":1791326125605,"version":"4.3.1"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","award":["HSR-4077-11-2016"],"award-info":[{"award-number":["HSR-4077-11-2016"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral anticancer therapies such as protein kinase inhibitors (PKIs) are increasingly prescribed in cancer care. We aimed to evaluate the impact of a pharmacist-led interprofessional medication adherence program (IMAP) on patient implementation (dosing history), persistence (time until premature cessation of the treatment) and adherence to 27 PKIs prescribed for various solid cancers, as well as the impact on patients\u2019 beliefs about medicines (BAM) and quality of life (QoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients (n = 118) were randomized 1:1 into two arms. In the intervention arm, pharmacists supported patient adherence through monthly electronic and motivational feedback, including educational, behavioral and affective components, for 12 months. The control arm received standard care plus EM without intervention. All PKIs were delivered in electronic monitors (EMs). Medication implementation and adherence were compared between groups using generalized estimating equation models, in which relevant covariables were included; persistence was compared with Kaplan\u2012Meier curves. Information on all treatment interruptions was compiled for the analysis. Questionnaires to evaluate BAM and QoL were completed among patients who refused and those who accepted to participate at inclusion, 6 and 12 months post-inclusion or at study exit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Day-by-day PKI implementation was consistently higher and statistically significant in the intervention arm (n = 58) than in the control arm (n = 60), with 98.1% and 95.0% (\u03943.1%, 95% confidence interval (CI) of the difference 2.5%; 3.7%) implementation at 6 months, respectively. The probabilities of persistence and adherence were not different between groups, and no difference was found between groups for BAM and QoL scores. No difference in BAM or QoL was found among patients who refused versus those who participated. The intervention benefited mostly men (at 6 months, \u03944.7%, 95% CI 3.4%; 6.0%), those younger than 60 years (\u03944.0%, 95% CI 3.1%; 4.9%), those who had initiated PKI more than 60 days ago before inclusion (\u03944.5%, 95% CI 3.6%; 5.4%), patients without metastasis (\u03944.5%, 95% CI 3.4%; 5.7%), those who were diagnosed with metastasis more than 2 years ago (\u03945.3%, 95% CI 4.3%; 6.4%) and those who had never used any adherence tool before inclusion (\u03943.8%, 95% CI 3.1%; 4.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The IMAP, led by pharmacists in the context of an interprofessional collaborative practice, supported adherence, specifically implementation, to PKIs among patients with solid cancers. To manage adverse drug events, PKI transient interruptions are often mandated as part of a strategy for treatment and adherence optimization according to guidelines. Implementation of longer-term medication adherence interventions in the daily clinic may contribute to the improvement of progression-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04484064\" xlink:type=\"simple\">NCT04484064<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0304573","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T13:55:27Z","timestamp":1717768527000},"page":"e0304573","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-3100","authenticated-orcid":true,"given":"Carole","family":"Bandiera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Diciolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Digklia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Stravodimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Cristina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Aedo-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Dolcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Sarivalasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasna","family":"Bouchaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5554-2988","authenticated-orcid":true,"given":"J\u00e9r\u00f4me","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8500-817X","authenticated-orcid":true,"given":"Jennifer","family":"Dotta-Celio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Paule","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"pone.0304573.ref001","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"H. Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"pone.0304573.ref002","article-title":"Annual report to the nation on the status of cancer, part 1: National cancer statistics","author":"K.A. Cronin","year":"2022","journal-title":"Cancer"},{"key":"pone.0304573.ref003","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"LiverTox","year":"2012"},{"issue":"10","key":"pone.0304573.ref004","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"A. Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0304573.ref005","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.21.02529","article-title":"Call to Action for Improving Oral Anticancer Agent Adherence","volume":"40","author":"L.A. Levit","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0304573.ref006","doi-asserted-by":"crossref","first-page":"e13164","DOI":"10.1111\/ecc.13164","article-title":"Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer","volume":"28","author":"E.M. Ciruelos","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"5","key":"pone.0304573.ref007","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"B. Vrijens","year":"2012","journal-title":"British journal of clinical pharmacology"},{"key":"pone.0304573.ref008","article-title":"Association between adherence to oral therapies in cancer patients and clinical outcome: A systematic review of the literature","author":"R. Lasala","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"pone.0304573.ref009","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"A.R. Ibrahim","year":"2011","journal-title":"Blood"},{"issue":"14","key":"pone.0304573.ref010","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"D. Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0304573.ref011","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/pds.4012","article-title":"The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer","volume":"25","author":"A.N. Winn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"pone.0304573.ref012","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"D.L. Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0304573.ref013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.urology.2022.07.012","article-title":"Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC)","volume":"168","author":"M.A. Dinan","year":"2022","journal-title":"Urology"},{"issue":"3","key":"pone.0304573.ref014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","article-title":"A Systematic Review of Adherence to Oral Antineoplastic Therapies","volume":"21","author":"J.A. Greer","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"pone.0304573.ref015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/14737140.2016.1159515","article-title":"Medication adherence to oral anticancer drugs: systematic review","volume":"16","author":"W.C. Huang","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"pone.0304573.ref016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ecc.12124","article-title":"Adherence to oral antineoplastic agents by cancer patients: definition and literature review","volume":"23","author":"F. Bassan","year":"2014","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"6","key":"pone.0304573.ref017","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ctrv.2012.12.014","article-title":"Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review","volume":"39","author":"M. Verbrugghe","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"pone.0304573.ref018","article-title":"A review of factors influencing non-adherence to oral antineoplastic drugs","author":"X. Skrabal Ross","year":"2020","journal-title":"Supportive Care in Cancer"},{"issue":"5","key":"pone.0304573.ref019","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jnci\/djz244","article-title":"Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review","volume":"112","author":"S.M. Rosenberg","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"pone.0304573.ref020","first-page":"85","article-title":"Patient adherence to oral anticancer drugs: an emerging issue in modern oncology","volume":"66","author":"V. Foulon","year":"2011","journal-title":"Acta Clinica Belgica"},{"issue":"3","key":"pone.0304573.ref021","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.sapharm.2014.08.006","article-title":"Interventions for adherence with oral chemotherapy in hematological malignancies: A systematic review","volume":"11","author":"J. Kavookjian","year":"2015","journal-title":"Res Social Adm Pharm"},{"issue":"1567","key":"pone.0304573.ref022","article-title":"A Novel Approach to Better Characterize Medication Adherence in Oral Anticancer Treatments","volume":"9","author":"M.P. Schneider","year":"2019","journal-title":"Frontiers in Pharmacology"},{"key":"pone.0304573.ref023","doi-asserted-by":"crossref","first-page":"103546","DOI":"10.1155\/2015\/103546","article-title":"Interdisciplinary Medication Adherence Program: The Example of a University Community Pharmacy in Switzerland","volume":"2015","author":"M. Lelubre","year":"2015","journal-title":"Biomed Res Int"},{"issue":"1","key":"pone.0304573.ref024","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1186\/s12913-018-3641-5","article-title":"Implementation study of an interprofessional medication adherence program for HIV patients in Switzerland: quantitative and qualitative implementation results","volume":"18","author":"M. Lelubre","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"pone.0304573.ref025","doi-asserted-by":"crossref","first-page":"ofaa323","DOI":"10.1093\/ofid\/ofaa323","article-title":"An Adherence-Enhancing Program Increases Retention in Care in the Swiss HIV Cohort","volume":"7","author":"S. Kamal","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"pone.0304573.ref026","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00004872-200102000-00022","article-title":"Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions","volume":"19","author":"M. Burnier","year":"2001","journal-title":"J Hypertens"},{"issue":"1","key":"pone.0304573.ref027","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M18-0543","article-title":"ESPACOMP Medication Adherence Reporting Guideline (EMERGE)","volume":"169","author":"S. De Geest","year":"2018","journal-title":"Ann Intern Med"},{"key":"pone.0304573.ref028","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"K.F. Schulz","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"pone.0304573.ref029","doi-asserted-by":"crossref","first-page":"e30090","DOI":"10.2196\/30090","article-title":"Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data","volume":"10","author":"C. Bandiera","year":"2021","journal-title":"JMIR Res Protoc"},{"issue":"1","key":"pone.0304573.ref030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010316","article-title":"Adherence to the CDK 4\/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study","volume":"15","author":"C. Bandiera","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"pone.0304573.ref031","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1037\/0278-6133.25.4.462","article-title":"An information-motivation-behavioral skills model of adherence to antiretroviral therapy","volume":"25","author":"J.D. Fisher","year":"2006","journal-title":"Health Psychol"},{"issue":"4","key":"pone.0304573.ref032","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1016\/j.sapharm.2021.06.010","article-title":"Response to the first wave of the COVID-19 pandemic in the community pharmacy of a University Center for Primary Care and Public Health","volume":"18","author":"A. Bourdin","year":"2022","journal-title":"Res Social Adm Pharm"},{"issue":"6","key":"pone.0304573.ref033","first-page":"335","volume":"64","author":"E. Fall","year":"2014","journal-title":"Validation of the French version of the Beliefs about Medicines Questionnaire (BMQ) among diabetes and HIV patients"},{"issue":"1","key":"pone.0304573.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08870449908407311","article-title":"The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication","volume":"14","author":"R. Horne","year":"1999","journal-title":"Psychology & Health"},{"issue":"5","key":"pone.0304573.ref035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"N.K. Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"pone.0304573.ref036","volume-title":"The EORTC QLQ-C30 Scoring Manual","author":"on and b.o.t.E.Q.o.L. Group","year":"2001","edition":"3"},{"issue":"2","key":"pone.0304573.ref037","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"P.A. Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"pone.0304573.ref038","article-title":"Estimation of adherence to medication treatment in presence of censoring","author":"J. Pasquier","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"pone.0304573.ref039","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"N. Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"issue":"7","key":"pone.0304573.ref040","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/pds.5258","article-title":"New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices","volume":"30","author":"K. Luijken","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pone.0304573.ref041","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/TP.0000000000002359","article-title":"Gender Differences in Medication Adherence Among Adolescent and Young Adult Kidney Transplant Recipients","volume":"103","author":"J. Boucquemont","year":"2019","journal-title":"Transplantation"},{"issue":"4","key":"pone.0304573.ref042","doi-asserted-by":"crossref","first-page":"e5641","DOI":"10.1097\/MD.0000000000005641","article-title":"Nonadherence to antihypertensive drugs: A systematic review and meta-analysis","volume":"96","author":"T.M. Abegaz","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"pone.0304573.ref043","article-title":"Impact of sex differences in co-morbidities and medication adherence on outcome in 25 776 heart failure patients","author":"M.T. Gurgoze","year":"2020","journal-title":"ESC Heart Fail"},{"key":"pone.0304573.ref044","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2147\/PPA.S260562","article-title":"Interventions to Improve Adherence to Cardiovascular Medication: What About Gender Differences? A Systematic Literature Review","volume":"14","author":"M. Vervloet","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"pone.0304573.ref045","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1186\/s12885-018-5066-2","article-title":"A systematic review of non-standard dosing of oral anticancer therapies","volume":"18","author":"F. Djebbari","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"pone.0304573.ref046","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1078155214567163","article-title":"Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review","volume":"22","author":"J.J. Bergsbaken","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"pone.0304573.ref047","article-title":"Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs","author":"R. Lasala","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"7","key":"pone.0304573.ref048","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071317","article-title":"Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer","volume":"14","author":"P. Courlet","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"pone.0304573.ref049","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctrv.2013.07.004","article-title":"Adherence enhancing interventions for oral anticancer agents: a systematic review","volume":"40","author":"T. Mathes","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"43","key":"pone.0304573.ref050","first-page":"iii, ix","article-title":"Contamination in trials of educational interventions","volume":"11","author":"M.R. Keogh-Brown","year":"2007","journal-title":"Health Technol Assess"},{"issue":"7","key":"pone.0304573.ref051","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/dme.12439","article-title":"Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with Type 2 diabetes: evidence from a randomized controlled trial","volume":"31","author":"M. Vervloet","year":"2014","journal-title":"Diabet Med"},{"issue":"5","key":"pone.0304573.ref052","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/cncr.27854","article-title":"Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials","volume":"119","author":"D. Hui","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"pone.0304573.ref053","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/j.clbc.2018.09.002","article-title":"Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive\/HER2-Negative Metastatic Breast Cancer","volume":"19","author":"G.A. Watson","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"pone.0304573.ref054","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-020-01376-z","article-title":"Revisiting time to translation: implementation of evidence-based practices (EBPs) in cancer control","volume":"32","author":"S. Khan","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"3","key":"pone.0304573.ref055","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.japh.2020.12.005","article-title":"Pharmacist-led collaborative medication management programs for oral antineoplastic therapies: A systematic literature review","volume":"61","author":"D.G. Passey","year":"2021","journal-title":"J Am Pharm Assoc (2003)"},{"key":"pone.0304573.ref056","doi-asserted-by":"crossref","DOI":"10.3389\/ijph.2022.1605204","article-title":"Swiss Priority Setting on Implementing Medication Adherence Interventions as Part of the European ENABLE COST Action","volume":"67","author":"C. Bandiera","year":"2022","journal-title":"International Journal of Public Health"},{"issue":"1","key":"pone.0304573.ref057","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12885-017-3110-2","article-title":"Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists","volume":"17","author":"L. Timmers","year":"2017","journal-title":"BMC Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T13:56:00Z","timestamp":1717768560000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304573"}},"subtitle":[],"editor":[{"given":"Mabel","family":"Aoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304573","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}